Viking’s stock pops as obesity-drug contender drags down Eli Lilly, Novo Nordisk
Viking Therapeutics Inc’s shares gained about 15% premarket on Thursday after the company signaled progress on an experimental obesity drug that could accelerate its development timeline.
